News | December 17, 2013

Soluble Therapeutics Closes On Second Investment Round

Proceeds to be used to Finance Expansion and Collaborations with Large CMO and Large Pharma

Soluble Therapeutics, Inc. a Birmingham, Alabama–based CRO and product development company specializing in formulation optimization for protein-based therapeutics, announces that it has secured a second round of investment to support the expansion of its formulation development business. This expansion is necessary to meet continued demand for the company’s large molecule formulation service, as well as to accommodate two new research collaborations, one with a global Pharmaceutical Contract Manufacturing Organization (CMO) and one with a large US based pharmaceutical company, that could lead to exclusive licensing deals for the HSC Technology.

The investment comes from the Targeted Technology Fund II out of San Antonio, TX - a group that has participated in prior funding rounds for the company. Soluble Therapeutics’ CEO, Dr. Joseph Garner, states “This funding represents a vote of confidence in the work that Soluble Therapeutics is doing and will allow us to continue expanding upon our initial success. We are very excited about the research collaborations kicking off in 2014 and further demonstrating the value of the HSC Technology in the marketplace.”

About Soluble Therapeutics, Inc.
Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC Technology. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics’ management team consists of science industry professionals bringing over 60 years of combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first to introduce protein formulation solutions that deliver the price and performance advantages of the HSC Technology. For more information, visit http://www.soluble-therapeutics.com

About The HSC Technology
The HSC Technology is a combination of high-throughput protein screening instrumentation and an artificial neural network. The instrumentation performs Self-Interaction Chromatography (SIC) to measure the effects of additives and excipients on the B22 value of proteins in solution. Positive B22 values are correlated with increased solubility and stability for the protein under study. By performing high-throughput SIC, the HSC Technology can do the work of 4,000 formulation assays in approximately one month. The HSC Technology is available on a contract research basis, or the HSC System can be purchased for use in laboratories across the world.

SOURCE: Soluble Therapeutics, Inc.

Newsletter Signup
Newsletter Signup